Cardiac hypertrophy is an independent risk factor for heart failure. Recent studies on gene regulation of proteins have involved intracellular Ca 2+ homeostasis. The Ca 2+ -sensitive phosphatase, calcineurin, is one potential regulator of the hypertrophic response, so we aimed to investigate the calcineurin-dependent signal pathway at different stages of hypertrophy in human myocardium. We found the calcineurin pathway to be significantly activated in hypertrophic compared with non-hypertrophic myocardium as demonstrated by increased calcineurin activity and expression of calcineurin A-b and B, and GATA-4, and a shift of phosphorylated cytoplasmic NFAT-3 into the nucleus as dephosphorylated nuclear NFAT-3. There was a tendency for these changes to be more pronounced in the decompensated compared with the compensated hypertrophic myocardium. The present study provides evidence for significant activation of the Ca 2+ -triggered calcineurin pathway in hypertrophic humans. Already present in compensated hypertrophy it showed a tendency to a further increase following transition to decompensated hypertrophy. KEY WORDS: CALCINEURIN; GATA-4; NFAT-3; HUMAN MYOCARDIUM; HYPERTROPHY; HEART FAILURE H Diedrichs, J Hagemeister, M Chi et al. Calcineurin/NFAT signalling cascade in hypertrophic myocardium
Introduction
Cardiac hypertrophy is an adaptive response of the heart to a variety of pathological stimuli, including hypertension, myocardial infarction, endocrine disorders and perturbations in sarcomeric function due to altered expression or mutations of contractile proteins. Prolonged hypertrophy is associated with decompensation and heart failure. Recent epidemiological studies have revealed that cardiac hypertrophy is an independent risk factor for the development of heart failure. 1 Several studies have identified alterations in Ca 2+ handling in the hypertrophied and failing myocardium. 2 -4 A prolonged Ca 2+ transient and elevated diastolic intracellular Ca 2+ have been described in failing human myocardium. 3, 5 These alterations are in accordance with a decreased Ca 2+ uptake and reduced sarcoplasmic reticulum Ca 2+ 4, 6, 7 Intracellular Ca 2+ is regarded as one potential central factor associated with cardiac hypertrophy and the progressive nature of heart failure.
Alterations in intracellular Ca 2+ homeostasis might act as an intracellular second messenger to initiate hypertrophy. Currently the effects of elevated intracellular Ca 2+ on gene regulation have become more and more the subject of interest. In this context calcineurin, a Ca 2+ /calmodulindependent protein phosphatase has been suggested as playing an important role in the regulation of the hypertrophic response.
The involvement of this signalling pathway in cardiac hypertrophy has been demonstrated in transgenic mice that overexpress either active calcineurin catalytic subunit or a constitutively nuclear NFAT-3 mutant protein (N-terminal truncation), and thus develop massive cardiac hypertrophy which quickly transforms to heart failure leading to death. 8 A number of these features can also be duplicated using in vitro cardiomyocyte models of cardiac hypertrophy. 9 It has also been demonstrated that calcineurin activity is increased in compensated hypertrophied human myocardium and end-stage heart failure. 10, 11 Furthermore, we recently showed an increased calcineurin activity, an increased expression of calcineurin B, GATA-4 and a nuclear translocation of NFAT-3 in the failing human heart with dilated cardiomyopathy. 12 Aside from these data on the calcineurin pathway in the terminally failing human heart there are a lack of data regarding its involvement in the earlier stages of the disease process, i.e. myocardial hypertrophy. We, therefore, investigated key markers of the calcineurin signalling cascade in human myocardium from patients with coronary artery disease (CAD) but without myocardial hypertrophy (control group) and from patients with pressure induced myocardial hypertrophy (aortic valve stenosis) with normal or compromised ventricular function.
Patients and methods

PATIENTS AND MYOCARDIAL TISSUE
Patients gave their informed written consent before participating in the study, which was approved by the ethics committee of the University of Cologne.
Transmural myocardial biopsies were obtained by cardiac surgeons (Department of Cardiothoracic Surgery, University of Cologne) from the anterior segment of the left ventricular wall of patients undergoing coronary artery bypass surgery (n = 6) or aortic valve replacement (n = 12). Surgical biopsies were gained directly before the heart-lung machine was installed. Excised tissue was immediately submersed in liquid nitrogen and stored at -80 o C. This process ensured that the enzymatic activity in the myocardium did not degenerate and that there was a highly standardized set of tissue for investigation.
Control myocardium was obtained from coronary artery bypass patients who had a normal left ventricular function (ejection fraction [EF] > 60% and no regional hypokinesia) without cardiac hypertrophy, as shown by preoperative echocardiography (n = 6). Hypertrophic myocardium was obtained from patients undergoing aortic valve surgery. Preoperative diagnosis of these patients was aortic valve stenosis, and echocardiographic examination showing a septal + posterior wall thickness > 25 mm. According to left ventricular function, the hypertrophic myocardium patients were divided into two groups: hypertrophic H Diedrichs, J Hagemeister, M Chi et al. Calcineurin/NFAT signalling cascade in hypertrophic myocardium myocardium with compensated left ventricular function (EF > 60%; n = 6) and hypertrophic myocardium with reduced left ventricular function (EF < 60%; n = 6).
PROTEIN HOMOGENATES
The frozen biopsies from the left ventricular wall were broken with a hammer and reduced to a powder in liquid nitrogen using a Mikro-Dismembrator U (B Braun Biotech International, Melsungen, Germany). Between 50 and 100 mg of powder was transferred into a glass-Teflon ® homogenizer and thawed on ice in three times the volume of chilled preparation buffer (300 mM sucrose, 1 mM phenylmethylsulfonyl fluoride [PMSF], 20 mM piperazine-N,N'bis (2-ethanesulfonic acid) [PIPES], 10 mM ethylenediamine tetraacetic acid [EDTA], 50 mM NaH 2 PO 4 , pH 7.4) as previously described. 4, 13 Samples were minced using an Ultra-Turrax ® (IKA ® Works, Staufen, Germany) at 4°C (three runs of 30 s). The obtained homogenate was diluted further with an equal volume of storage buffer (400 mM sucrose, 5 mM 4-(2-hydroxyethyl)-1piperazine-ethanesulfonic acid [HEPES], 5 mM Tris, 10 mM EDTA, 50 mM NaH 2 PO 4 , pH 7.2), and was then frozen in liquid nitrogen and stored at -80°C until use in Western blot analysis.
Protein concentration was determined by Bradford´s assay in a 96-well plate at 405 nm absorbance. Samples and standard bovine serum albumin (BSA) were run in duplicate and the homogenates were diluted until the optimal protein concentration (2500 µg/ml) for Western blot was obtained.
NUCLEAR AND CYTOPLASMIC EXTRACTS
As described by Deryckere and Gannon, 14 between 30 and 40 mg of human myocardial tissue, which had been frozen in liquid nitrogen, was broken with a hammer, transferred to a Mikro-Dismembrator U (B Braun Biotech International) and reduced to a powder under agitation at 1600 rpm for 2 min. All the following steps were carried out on ice and centrifugations were at 0°C. The thawed powder was homogenized in 5 ml of solution A (0.6% Nonidet ® P-40, 150 mM NaCl, 10 mM HEPES pH 7.9, 1 mM EDTA, 0.5 mM PMSF). After centrifugation at 229 g for 30 s, the supernatant was incubated for 5 min on ice and then centrifuged again for 5 min at 2061 g. The pelleted nuclei were resuspended in 300 µl of solution B (25% glycerol, 20 mM HEPES pH 7.9, 420 mM NaCl, 1.2 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM dithiothreitol [DTT], 0.5 mM PMSF, 2 mM benzamidine, 5 µg/ml of each of the following protease inhibitors: pepstatin, leupeptin and aprotinin). In order to confirm that intact nuclei had been separated from the cytoplasmic extraction, one drop of the suspension in mounting medium containing 4',6-diamidino-2-phenylindole (DAPI) was observed under a fluorescence microscope. The suspension was then incubated on ice for 20 min for high-salt extraction. The lysed nuclei were transferred to an Eppendorf tube and cellular debris was separated by a 15 s centrifugation. The supernatant containing the DNA-binding proteins was then frozen in liquid nitrogen and stored at -80 o C. [BSA] , 50 mM Tris pH 7.4) and B (as solution A but with 1 mM NiCl 2 and 10 µg/ml calmodulin) were dispensed into separate wells (95 µl/well) on a 96-well plate. Calmodulin and NiCl 2 were added to solution B and not to solution A (control) in order to obtain evidence that the phosphatase activity was only attributable to PPase-2B (and not for example to PPase-2A). Homogenate, prepared as described above, was diluted in enzyme dilution buffer (0.5 mg/ml acetylated BSA, 50 mM Tris pH 7.4) in a 1:20 ratio (final protein concentration, 125 µg protein/ml) and was then dispensed (5 µl) into the wells containing either solution A or B. The 96well plate had been pre-warmed and, after incubation for 15 min at 30°C the absorbance at 410 nm was measured. All samples were run in triplicate. To reduce measurement errors from interfering background substances (for example free phosphate) samples were assayed for linearity between phosphatase activity and protein concentration, and optimized protein concentrations were used for the final enzymatic assay. Calcineurin activity was calculated as phosphate released in the presence of calmodulin and Ni 2+ (sample with solution B) minus phosphate released without calmodulin and Ni 2+ (sample with solution A).
CALCINEURIN ENZYMATIC ACTIVITY
WESTERN BLOT ANALYSIS
To detect protein expression, immunoblots were performed as previously described. 4, 13 Preparations were thawed on ice and suspended with buffer (Tris-HCl 0.05 mol/l, 10% glycerol, 2% sodium dodecyl sulphate [SDS], 5% 2-mercaptoethanol, 0.05% bromophenol blue). The samples were subjected to 10% SDS-polyacrylamide gel electrophoresis (PAGE) (Hoefer SE 600; Hoefer Scientific Instruments, San Francisco, CA, USA) and then transferred to a polyvinylidene fluoride membrane (Bio-Rad Laboratories, Hercules, CA, USA). Immunoblotting was performed using polyclonal rabbit anti-calcineurin B (Upstate, Waltham, MA, USA), polyclonal rabbit anti-calcineurin A-β, polyclonal rabbit anti-GATA 4 and polyclonal goat anti-NFAT-3 antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) at dilutions of 1:2000, 1:300, 1:250 and 1:500, respectively. For detection of antibody binding an enhanced chemoluminescence assay (ECL Kit; Amersham, Little Chalfont, UK) was used and exposed to an X-ray film (Amersham). Protein expression was quantified after scanning the films into a personal computer and analysing the densitometric volume of the bands according to their signal intensity using a commercially available computer program (ImageQuant ® , Molecular Dynamics™, Sunnyvale, CA, USA). To avoid systematic errors due to overall changes in protein expression in cardiac hypertrophy, calsequestrin was used as an internal standard (marker protein) and the densitometric data were also normalized to protein concentration and individual calsequestrin expression.
STATISTICAL ANALYSIS
Data are presented as mean ± SE. Differences among groups were compared using an unpaired Student's t-test. The statistics software PRISM 2 ® (GraphPad Software Inc., San Diego, CA, USA) was used to analyse by linear regression the relationship between calcineurin B and EF. A P-value < 0.05 was considered to be statistically significant.
Results
There were no complications resulting from the biopsy procedure in any patient. Demographic and diagnostic data for the study participants are shown in Table 1 . 
CALCINEURIN ACTIVITY
The activity of calcineurin in hypertrophic and non-hypertrophic (control group) myocardium is summarized in Fig. 1 . Calcineurin activity was significantly increased in the hypertrophic myocardium group (n = 12) compared with the control group that had CAD but no signs of hypertrophy (n = 6) (0.144 ± 0.01 versus 0.085 ± 0.01 µmol Pi/min per µl, P < 0.05; Fig  1A) . Subgroup analysis in the hypertrophic myocardium group is summarized in Fig 1B. In the two subgroups, patients with compensated (EF > 60%, n = 6) and decompensated (EF < 60%, n = 6) hypertrophy had a significant increase in calcineurin activity (0.138 ± 0.019 and 0.146 ± 0.013 µmol Pi/min per µl, respectively) compared with the control group (P < 0.05). No significant difference between compensated and decompensated hypertrophic myocardium was observed, although there was very slightly higher calcineurin activity in the decompensated hypertrophic myocardium. 
CALCINEURIN PROTEIN EXPRESSION Calcineurin A-b
Protein expression of calcineurin A-β was significantly increased in the hypertrophic myocardium group (n = 12) compared with the control group (n = 6) (1346.9 ± 31.6 versus 1045.8 ± 33.1 densitometric units [DU]/µg protein, P < 0.05; Fig. 2A ). It was also significantly enhanced in decompensated hypertrophic myocardium (EF < 60%, n = 6) compared with the control group (1460.9 ± 19.6 versus 1045.8 ± 33.1 DU/µg protein, P < 0.05; Fig. 2B ). In compensated hypertrophic myocardium (EF > 60%, n = 6), calcineurin A-β protein expression was slightly, but not significantly, increased compared with the control group (1232.0 ± 43.3 versus 1045.8 ± 33.1 DU/µg protein).
Calcineurin B
Calcineurin B protein expression was also significantly increased in the hypertrophic myocardium group (n = 12) compared with Fig. 3A ). This significant difference was also found for both the compensated (EF > 60%, n = 6) and decompensated (EF < 60%, n = 6) hypertrophic myocardium groups individually (142.3 ± 3.06 DU/µg protein and 151.6 ± 5.4 DU/µg protein, respectively) when compared with the control (P < 0.05; Fig. 3B ). Furthermore, calcineurin B protein expression was significantly greater in hearts with decompensated hypertrophy compared with compensated hypertrophy (P < 0.05).
CALCINEURIN B PROTEIN EXPRESSION AND EJECTION FRACTION
Intracellular Ca 2+ homeostasis is altered in hypertrophic and failing myocardium and protein expression of the calcium-binding subunit of calcineurin (calcineurin B) is upregulated during development of hypertrophy and heart failure. We were therefore interested in whether or not the expression of calcineurin B was dependent on cardiac function, as measured by left ventricular EF in human myocardium. Using linear regression we found that there was a significant linear relationship between protein expression of calcineurin B and left ventricular EF (γ 2 = 0.69, P = 0.03; Fig. 4 ).
NUCLEAR TRANSLOCATION OF NFAT-3
Protein expression of NFAT-3 in cytoplasmic extracts was significantly decreased in biopsies from the hypertrophic myocardium group (n = 12) compared with the control group (n = 6) (1809.4 ± 88.2 versus 4177.3 ± 208.9 DU/µg protein, P < 0.05; Fig. 5A ). This decrease was significantly greater in decompensated (EF < 60%, n = 6) than in compensated (EF > 60%, n = 6) hypertrophic myocardium (2534.6 ± 66.7 versus 1084.2 ± 109.6 DU/µg protein, P < 0.05; Fig 5A) .
In contrast, NFAT-3 expression in nuclear extracts was significantly increased in hypertrophic myocardium (n = 12) compared with control myocardium (n = 6) (535.4 ± 2.2 versus 475.1 ± 3.1 DU/µg protein, P < 0.05; Fig. 5B ); this was also individually true for both the compensated (n = 6) (513.33 ± 4.07 DU/µg protein, P < 0.05) and decompensated (n = 6) (556.9 ± 2.2 DU/µg protein, P < 0.05) myocardium. There was, however, no significant difference between the compensated and decompensated stages of myocardial hypertrophy (Fig. 5B ).
CARDIAC-RESTRICTED ZINC FINGER TRANSCRIPTION FACTOR GATA-4 PROTEIN EXPRESSION
Specific antibody with an epitope corresponding to amino acids 328 -439 mapping at the carboxyl terminus of human GATA-4 was used in the Western blot analysis. A significant increase in protein expression of GATA-4 was seen in hypertrophic myocardium (n = 12) compared with control myocardium (n = 6) (1877.3 ± 52.4 versus 151.7 ± 19.7 DU/µg protein, P < Fig 6A) , and also between the compensated (n = 6) and decompensated (n = 6) hypertrophic subgroups compared with the control (1841.1 ± 48.7 and 2000.1 ± 55.2 DU/µg protein, respectively, versus 151.7 ± 19.7 DU/µg protein, P < 0.05; Fig 6B) . There was no significant difference in protein expression of GATA-4 between the compensated and decompensated hypertrophic subgroups. 
Discussion
Intracellular Ca 2+ elevation may be a trigger for cardiac hypertrophic signalling via the Ca 2+ -activated phosphatase, calcineurin. Initial in vitro and in vivo studies clearly demonstrated that the calcineurin cascade was a physiologically important signalling system. 8 Doubts remain, however, concerning its relevance for development of myocardial hypertrophy and progression to heart failure in humans. The present study demonstrated that activation of the calcineurin signalling cascade starts early in human myocardial hypertrophy. We found an increased calcineurin activity in human hearts with myocardial hypertrophy due to pressure overload (aortic valve stenosis) compared with control myocardium without hypertrophy (CAD). Accordingly, there was a translocation of nuclear factor of activated T cells (NFAT-3) into the nucleus during development of hypertrophy. Furthermore, we found increased protein expression of calcineurin A-β and B, and GATA-4. All these markers for an activated calcineurin signalling cascade showed significant alterations in hypertrophic human myocardium with and without impaired left ventricular function compared with the controls. With the exception of protein expression of calcineurin B, there were no significant differences between the hypertrophic samples but there was a perspicuous tendency to an increased level of activity in the calcineurin pathway with increment in left ventricular decompensation. Furthermore, the calcineurin B protein expression levels showed a linear correlation with the invasive measurement of left ventricular EF (Fig. 4) . In a meta-regression analysis that included our data from endstage human heart failure, 12 this linear correlation was also present (data not shown).
Our results are consistent with the report of Haq et al. 10 who found that calcineurin activity was increased in hypertrophied and end-stage failing hearts in humans. In their study, however, calcineurin activity in the failing human myocardium increased less than in the hypertrophic myocardium. They suggested that the increase in activity in failing hearts was due to increased expression whereas, in hypertrophied hearts, it may be due to both increased expression and increased specific activity.
Ritter et al. 15 observed the phosphorylation state of NFAT-2 in human hypertrophic myocardium and found an increase in dephosphorylation of NFAT-2 as biochemical evidence for increased calcineurin activity in vivo. Our results, regarding the translocation of NFAT-3 to the nucleus, may testify as well that NFAT-3 is dephosphorylated by activated calcineurin during development of hypertrophy and heart failure in humans. This is consistent with the study of Molkentin et al. 8 who found that NFAT-3 overexpression in transgenic mice produced myocardial hypertrophy.
In different animal models for myocardial hypertrophy and heart failure, data regarding the calcineurin pathway are still controversial. In a model of dilated heart failure, calcineurin enzymatic activity was upregulated. 16 This was combined with an increase in total calcineurin A protein content in the heart. 17 Pressure-overload hypertrophy in aortic-banded rats and exercise-induced cardiac hypertrophy in rats have been shown to be associated with an increase in calcineurin activity, 17 -20 although other groups have not been able to find increased cardiac calcineurin activity in response to pressure-overload stimulation or have even found reduced calcineurin activity in mice. 21, 22 These inconsistent results may be due to the use of different animal models and different causes for the development of hypertrophy. In order to avoid the influence of other factors, we selected all hypertrophic samples from patients in whom aortic valve stenosis was the cause of cardiac hypertrophy. Echocardiography and catheter examination provided exact clinical evidence of hypertrophy in the hearts. Furthermore, we were able to use invasive measurements of left ventricular EF to differentiate between hypertrophied hearts with normal and those with reduced left ventricular function as a sign for progression to heart failure. All this information, along with the highly standardized intraoperative removal of the myocardial biopsies were intended to ensure that we obtained an accurate reflection of the real situation in humans.
One problem pertinent to all studies in human tissue, however, is whether maximal calcineurin activity measured in tissue homogenates faithfully reflects in vivo activity. At present this cannot be answered directly but the translocation of NFAT-3 into H Diedrichs, J Hagemeister, M Chi et al. Calcineurin/NFAT signalling cascade in hypertrophic myocardium the nucleus during development of hypertrophy may give further evidence for increased calcineurin phosphatase activity (Fig. 5 ).
In the subgroup analysis of compensated and decompensated hypertrophic myocardium we found a tendency to a higher calcineurin activity and nuclear translocation of NFAT-3 in decompensated hypertrophic myocardium. This might be due to the small number of samples. Furthermore, the interaction between NFAT-3 and other transcription factors or protein kinases under calcineurin is very complex. For example, the myocyte enhancer factor (MEF) -2 family of transcriptional regulators has also been implicated in calcineurinmediated signalling in a variety of cell types. 23 Moreover, the mitogen-activated protein kinase group (c-Jun amino-terminal kinase [JNK] and p38 kinase) has been shown to phosphorylate NFATs. Chow et al. 24 reported that NFAT-4 was opposed by the JNK signal transduction pathway by being rephosphorylated and, therefore, retranslocated into the cytoplasm. To investigate eventual alteration in JNK we measured the protein expression of phosphorylated JNK in our heart samples and could not find any difference between control and hypertrophied myocardium (data not shown). Additional studies are required to test the interaction of the calcineurin-NFAT pathway with other signalling cascades.
GATA-4 is a cardiac-restricted zinc finger protein that plays an important role in cardiac development and gene expression. We found that protein expression of GATA-4 in human cardiac myocardium was significantly increased in hypertrophic compared with non-hypertrophic myocardium. This is consistent with data from Liang et al., 25 who showed that overexpression of GATA-4 in a transgenic mouse model led to myocardial hypertrophy in vivo. In addition, recent studies have suggested a functional interaction of GATA-4 with high affinity and specificity with NFAT transcription factors. 8, 26 Yang et al. 27 reported that electrical pacing results in the increased synthesis of GATA-4. Morimoto et al. 28 showed that NFAT and GATA-4 coactivated the endothelin-1 promoter. During haemodynamic overload-induced cardiac hypertrophy in vivo, GATA-4 is required for transcriptional activation of the genes for the β-myosin heavy chain and angiotensin II type Iα receptor. 29, 30 Although there is a lack of information regarding the detailed interaction of GATA-4 and NFAT-3 in human myocardium, all these data, along with our current study, provide evidence that GATA-4 is a critical transcription factor for the development of cardiac hypertrophy.
The calcineurin enzyme comprises a 59 -63 kDa catalytic subunit (calcineurin A) and a 19 kDa Ca 2+ -binding subunit (calcineurin B). Three mammalian calcineurin A genes have been identified (α, β and γ) 26, 31 and two of these, α and β, are expressed in human myocardium.
In human hypertrophied myocardium Ritter et al. 15 found decreased protein expression of calcineurin A-β and A-α (Western blotting with specific antibodies against the C-terminus). They interpreted these results as a post-translational modification of calcineurin A in the human hypertrophic heart; an autoinhibitory domain in the carboxyl terminal region is probably removed and, thereby, the catalytic activity of the remaining protein is increased.
The same type of antibody against calcineurin A-β was used in our study. In contrast to the study of Ritter et al., 15 however, calcineurin A-β protein in H Diedrichs, J Hagemeister, M Chi et al. Calcineurin/NFAT signalling cascade in hypertrophic myocardium hypertrophied hearts was significantly increased and this increase tended to be greater in decompensated than in compensated hypertrophic myocardium, although this difference was not statistically significant in our study.
Our data in human myocardium agree with investigations in animals and cell cultures from other groups. Taigen et al. 32 showed that stimulation with phenylephrine or angiotensin II significantly increased calcineurin enzymatic activity in cultured cardiomyocytes. This increased enzymatic activity was associated with an increase in both calcineurin A-β mRNA and protein levels. In addition, the calcineurin A-β gene was recently targeted in embryonic stem cells and used to generate homozygous null mice. Calcineurin A-β null mice had reduced cardiac calcineurin activity and demonstrated impaired hypertrophy in response to angiotensin II, isoprenaline or abdominal aortic constriction. 33 These data specifically implicate the involvement of the calcineurin A-β gene in regulating the hypertrophic response and support our data in human myocardium.
Since intracellular Ca 2+ is potentially regarded as having a central role in the development of cardiac hypertrophy we measured the expression of the Ca 2+ -binding subunit of calcineurin (calcineurin B). A sufficient increase in intracellular Ca 2+ levels activates calcineurin by binding calmodulin at this regulatory subunit. We found a significant increase in calcineurin B protein expression in hypertrophied human left ventricular myocardium that was even greater during development of impaired left ventricular function. Furthermore, there was a linear correlation between calcineurin protein level and left ventricular EF. This increased expression of the regulatory subunit could provide more binding sites for Ca 2+ and lead to increased calcineurin phosphatase activity when intracellular Ca 2+ levels rise during the development of hypertrophy and heart failure.
In summary, the present study is the first to our knowledge to investigate human myocardium at different functional stages of hypertrophy. Calcineurin activity in hypertrophic myocardium was increased compared with that in non-hypertrophic myocardium, and there was a tendency for a further increase to occur in hypertrophied hearts with a reduced left ventricular EF (< 60%). Elevation of calcineurin activity was concurrent with raised protein expression of calcineurin A-β, and the increase of calcineurin B paralleled patients' decrease in left ventricular function. As an indication of increased calcineurin phosphatase activity we found a shift of NFAT-3 into the nucleus during development of hypertrophy. In addition, protein expression of hypertrophyrelated cardiac-restricted zinc finger transcription factor (GATA-4) was significantly increased in compensated and decompensated hypertrophic human left ventricular myocardium, indicating involvement with the calcineurin/NFAT signalling cascade.
